Clinical Trials Logo

Clinical Trial Summary

Osteochondral defects (OCDs) of the talus have a significant impact on the quality of life of patients. When OCDs are of small nature (up to 15 mm in diameter), and have failed conservative management, surgical intervention may be necessary. For small cystic defects the current treatment is an arthroscopic bone marrow stimulation (BMS) procedure, during which the damaged cartilage is resected and the subchondral bone is microfractured (MF), in order to disrupt intraosseous blood vessels and thereby introduce blood and bone marrow cells into the debrided lesion, forming a microfracture fibrin clot, which contains a dilute stem cell population from the underlying bone marrow. This procedure has been reported to have a 75% successful long-term outcome. Recently, the additional use of biological adjuncts has become popular, one of them being bone marrow aspirate concentrate (BMAC) from the iliac crest. BMAC consists of mesenchymal stem cells, hematopoietic stem cells and growth factors, which may therefore theoretically improve the quality of subchondral plate and cartilage repair. The current evidence for treating talar OCDs with BMS plus BMAC is limited and heterogeneous. It is unclear to what extent the treatment of talar OCDs with BMS plus BMAC is beneficial in comparison to BMS alone.


Clinical Trial Description

Osteochondral defects (OCDs) of the talus have a significant impact on the quality of life of patients. When OCDs are of small nature (up to 15 mm in diameter), and have failed conservative management, surgical intervention may be necessary. For small cystic defects the current treatment is an arthroscopic bone marrow stimulation (BMS) procedure, during which the damaged cartilage is resected and the subchondral bone is microfractured (MF), in order to disrupt intraosseous blood vessels and thereby introduce blood and bone marrow cells into the debrided lesion, forming a microfracture fibrin clot, which contains a dilute stem cell population from the underlying bone marrow. This procedure has been reported to have a 75% successful long-term outcome. Recently, the additional use of biological adjuncts has become popular, one of them being bone marrow aspirate concentrate (BMAC) from the iliac crest. BMAC consists of mesenchymal stem cells, hematopoietic stem cells and growth factors, which may therefore theoretically improve the quality of subchondral plate and cartilage repair. The current evidence for treating talar OCDs with BMS plus BMAC is limited and heterogeneous. It is unclear to what extent the treatment of talar OCDs with BMS plus BMAC is beneficial in comparison to BMS alone. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04475341
Study type Interventional
Source Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Contact Jari Dahmen, MD, BSc
Phone +31638522988
Email j.dahmen@amsterdamumc.nl
Status Not yet recruiting
Phase N/A
Start date September 1, 2020
Completion date September 2, 2024

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT03856021 - Microfracture vs. Microfracture and BMAC for Osteochondral Lesions of the Talus N/A
Not yet recruiting NCT05476692 - Clinical Outcome of Surgical Treatment for Osteochondral Lesions of the Talus
Active, not recruiting NCT02345564 - Clinical and Radiological Results of Osteochondral Repair Using MaioRegen in Knee and Ankle Surgery N/A
Active, not recruiting NCT01347892 - DeNovo NT Ankle LDC Study N/A
Active, not recruiting NCT03750253 - Extracorporeal Shock Wave Therapy for Pain-Relief After Arthroscopy for Osteochondral Lesions of the Talus N/A
Recruiting NCT06358807 - Microfracture With Platelet Rich Plasma Gel Injection for Osteochondral Lesion of the Talus N/A
Completed NCT04194970 - Monitoring of Weight Bearing Protocols Via Mobile Application and Pressure Sensors. N/A
Enrolling by invitation NCT02338375 - Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product Phase 0
Withdrawn NCT05741983 - AMIC vs. MFx in the Ankle N/A
Enrolling by invitation NCT04132076 - Treatment Outcome After Ankle Joint Surgeries